Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates

Ambrx Biopharma To Be Acquired by Johnson & Johnson

Skadden is advising Ambrx Biopharma on its $2 billion acquisition by Johnson & Johnson.
BACK TO TOP